HK Stock Market Move | CARSGEN-B (02171) surged over 9% in early trading. The company presented the research results of Cezvoquinolone solution at the ESMO Annual Meeting in 2025.

CARSGEN-B (02171) rose more than 9% in the early trading, with an increase of 9.49% as of the time of drafting, reaching 17.66 Hong Kong dollars, with a turnover of 11.9521 million Hong Kong dollars. In terms of news, Csjj Pharmaceutical announced that the results of the Phase Ib registration clinical trial of Zevokeyolunsi injection for the adjuvant treatment of pancreatic cancer (PC) conducted in China have been presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. This trial is the world's first exploration of CAR-T cell therapy for adjuvant treatment of solid tumors. It is worth noting that on September 20, the National Medical Insurance Administration announced that the first edition of the expert review of the Commercial Insurance Innovative Drug Catalog has been completed. It is reported that 5 CAR-T drugs, including Zevokeyolunsi from Csjj Pharmaceutical, have all passed the expert review and are expected to enter the basic medical insurance directory and commercial insurance innovative drug catalog range this year.